Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Evolus, Inc.

NASDAQ: EOLS · Life Sciences · 3 alerts · CIK 1570562

Share price
$6.63Close, Nov 16
Market cap
$439M
Shares outstanding
66.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Evolus, Inc. filings on SEC EDGAR ↗

4:58 PM ET 10-Q
Financial Results ▶ Call

Evolus Q3 2026 Results: Net Loss of $12.5M, Loss Narrows

Evolus, Inc. is an aesthetic neurotoxin company that has incurred significant losses since inception and relies heavily on its licensing agreements with Daewoong and Symatese. The company is currently focused on the commercial success of Jeuveau and the regulatory approval process for its Evolysse product line.

Key figure
Net loss $12.5M
4:12 PM ET 8-K
Financial Results

Evolus Financial Results

Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.

Term
Q3 2026

“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”

David Moatazedi, President and Chief Executive Officer

“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”

David Moatazedi, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.